This signal suggests that TIL cell therapy is a potentially viable treatment option for patients with advanced metastatic NSCLC.

Current Study

Methods

Study Design

We report data from Cohort 3B, investigating LN-145 TIL cell therapy in patients with advanced NSCLC from a multicenter phase 2 study with inhabitants in 11 countries.

Cohort 3B Patients

Eligible patients (n=28) received LN-145 monotherapy. A total of 2 patients withdrew consent before infusion, leaving 26 patients for safety analysis and 24 patients for efficacy.

Eligibility criteria:

- Age ≥18 years
- ECOG performance status 0–1
- Performance status <10% for 2 years
- At least one measurable lesion

Data cutoff: 24 August 2021

Introduction

Results

Table 3. Efficacy

<table>
<thead>
<tr>
<th>Response</th>
<th>COV-19 Cohort 3B</th>
<th>ORR</th>
<th>CR, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR</td>
<td>21 (78.6)</td>
<td>16/28 (57.1%)</td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>5/28 (18%)</td>
<td>75% (95% CI)</td>
<td></td>
</tr>
<tr>
<td>DCR</td>
<td>7/28 (25%)</td>
<td>25% (95% CI)</td>
<td></td>
</tr>
</tbody>
</table>

Table 4. TIL TCR Repertoire Analyses

For more information, please contact Madan Jagasia, MD, MS, MBCHB madan.jagasia@iovance.com

Figure 1. Patient Journey and Central Gen 2 GMP Manufacturing

Figure 2. Cohort 3B Patient Treatment Schema

Figure 3. Patient Disposition

Figure 4. Adverse Events Over Time (FAS)

Figure 5. Best Percentage Change from Baseline in Target Lesion Sum of Diameters (Efficacy-Evaluable Set)

Figure 6. Time to First Response, Duration of Response, and Time on Efficacy Assumption for Confirmed Responders Who Achieved PR or Better

Figure 7. Percentage Change from Baseline in Target Lesion Sum of Diameters (FAS)